Randomized Trialhigh evidence
Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial.
JAMA cardiology·July 29, 2026·PMID 42525404
Why it mattersATTR-CM causes progressive heart failure and poor quality of life. This analysis provides patient-centered evidence that acoramidis not only reduces mortality and hospitalizations but also preserves health status, supporting its role in modifying disease trajectory.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled